Literature DB >> 21892670

Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens.

Claudia Marchetti1, Filippo Bellati, Angela Musella, Chiara Napoletano, Giorgia Perniola, Violante Di Donato, Sandro Pignata, Marianna Nuti, Pierluigi Benedetti Panici.   

Abstract

We present two cases of advanced ovarian cancer treated with neoadjuvant chemotherapy with standard tri-weekly carboplatin and paclitaxel. Therapy was converted to weekly regimens because of disease progression, resulting in disease response. Weekly regimens could overcome drug resistance and this strategy should be attempted before abandoning first-line chemotherapy in favor of palliation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21892670     DOI: 10.1007/s10147-011-0300-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  25 in total

1.  Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.

Authors:  Yoh Watanabe; Hidekatsu Nakai; Haruhiko Ueda; Hiroshi Hoshiai
Journal:  Gynecol Oncol       Date:  2005-02       Impact factor: 5.482

2.  Diagnostic open laparoscopy in the management of advanced ovarian cancer.

Authors:  Roberto Angioli; Innocenza Palaia; Marzio Angelo Zullo; Ludovico Muzii; Natalina Manci; Marco Calcagno; Pierluigi Benedetti Panici
Journal:  Gynecol Oncol       Date:  2005-12-01       Impact factor: 5.482

3.  Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

Authors:  Maurie Markman; James Hall; Daniel Spitz; Sheldon Weiner; Linda Carson; Linda Van Le; Mark Baker
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study.

Authors:  Pierluigi Benedetti Panici; Innocenza Palaia; Marialida Graziano; Filippo Bellati; Natalina Manci; Roberto Angioli
Journal:  Oncology       Date:  2010-02-24       Impact factor: 2.935

6.  Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects.

Authors:  C H Wu; C H Yang; J N Lee; S C Hsu; E M Tsai
Journal:  Int J Gynecol Cancer       Date:  2001 Jul-Aug       Impact factor: 3.437

7.  Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery.

Authors:  P Benedetti Panici; G Perniola; R Angioli; M A Zullo; N Manci; I Palaia; F Bellati; F Plotti; M Calcagno; S Basile
Journal:  Int J Gynecol Cancer       Date:  2007-04-08       Impact factor: 3.437

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.

Authors:  R Sharma; J Graham; H Mitchell; A Brooks; S Blagden; H Gabra
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

10.  Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.

Authors:  Chiara Napoletano; Filippo Bellati; Rachele Landi; Simona Pauselli; Claudia Marchetti; Valeria Visconti; Patrizio Sale; Marco Liberati; Aurelia Rughetti; Luigi Frati; Pierluigi Benedetti Panici; Marianna Nuti
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

View more
  1 in total

1.  Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.

Authors:  Andrea Milani; Rebecca Kristeleit; Mary McCormack; Fharat Raja; Daniela Luvero; Martin Widschwendter; Nicola MacDonald; Tim Mould; Adeola Olatain; Allan Hackshaw; Jonathan A Ledermann
Journal:  ESMO Open       Date:  2017-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.